| Bioactivity | Vobarilizumab (ALX-0061) is an anti-IL-6R monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis[1][2][3]. |
| Invitro | Vobarilizumab 显示出对 sIL-6R 的优先结合亲和力 (与 mIL-6R 相比) [2]。Vobarilizumab (0-10 nM) 阻断重组 hIL-6 与重组 hsIL-6R 的相互作用[3]。Vobarilizumab (0-100 nM) 可抑制 TF-1 细胞的增殖[3]。 |
| In Vivo | Vobarilizumab (0.4-10 mg/kg，静脉注射) 抑制食蟹猴中 hIL-6 诱导的炎症[3]。Vobarilizumab (0.4-10 mg/kg，静脉注射) 通过与食蟹猴的血清白蛋白结合显示出长期暴露[3]。 Animal Model: |
| Name | Vobarilizumab |
| CAS | 1628814-88-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kerschbaumer A, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020 Jun;79(6):744-759. [2]. M. Van Roy, et al. FRI0021 Alx-0061, an anti-IL-6r nanobody® for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab. Ann Rheum Dis. 2013. 72 (3). [3]. Van Roy M, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17(1):135. |